Using different proteolytic enzymes to digest antibody and its impact on stability of antibody mimetics

Article


Khalili, H. 2020. Using different proteolytic enzymes to digest antibody and its impact on stability of antibody mimetics. Journal of Immunological Methods. 489 (Art. 112933). https://doi.org/10.1016/j.jim.2020.112933
AuthorsKhalili, H.
Abstract

There are opportunities to formulate antibodies as solid-state depots for local therapy, which would minimise large systemic doses that are typically required. We have developed antibody mimetics known as Fab-PEG-Fab (FpF) that display similar binding affinity and functional activity as IgG antibodies. For head-to-head comparison between FpF and IgG, FpF is prepared from the Fabs obtained by enzymatic digestion of IgGs. Here, we report for the first time that using different enzymes to proteolytically digest IgG plays an important role in stability profile of the obtained Fabs leading in different stability profiles of the final conjugated product such as FpF. We prepared an anti-vascular endothelial growth factor (VEGF) FpF from either clinical Fabrani (ranibizumab) or Fabs obtained by enzymatic digestion of bevacizumab (IgG) using immobilised papain and gingisKHANTM (KGP) enzyme. The stability of FpFs was then studied after being lyophilised in comparison with both ranibizumab and bevacizumab. Lyophilisation is being evaluated to produce solid material that can be used for depot fabrication. We observed that using immobilised papain to digest IgG resulted in the heterogenous isomers Fab leading to the preparation of heterogenous FpFbeva-papain mimetic that underwent aggregation during lyophilisation. However, using KGP enzyme generated a homogenous intact Fabbeva-KGP as determined by mass spectral analysis. Interestingly, the FpF mimetics prepared from the homogenous Fabs (Fabrani and Fabbeva-KGP), displayed greater stability compared to their starting bevacizumab and ranibizumab after being lyophilised as determined by DLS analysis. There is a potential to lyophilize FpFs to be used to fabricate solid-state depots.

JournalJournal of Immunological Methods
Journal citation489 (Art. 112933)
ISSN0022-1759
Year2020
PublisherElsevier
Accepted author manuscript
License
File Access Level
Anyone
Digital Object Identifier (DOI)https://doi.org/10.1016/j.jim.2020.112933
Publication dates
Online21 Nov 2020
Publication process dates
Accepted17 Nov 2020
Deposited23 Nov 2020
Copyright holder© 2020 Elsevier
Permalink -

https://repository.uel.ac.uk/item/88v4q

Restricted files

Accepted author manuscript

  • 13
    total views
  • 0
    total downloads
  • 1
    views this month
  • 0
    downloads this month

Export as

Related outputs

Protein modification by bis-alkylation
Picken, C., Awwad, S., Zloh, M., Khalili, H. and Brocchini, S. 2020. Protein modification by bis-alkylation. in: Pasut, G. and Zalipsky, S. (ed.) Polymer-Protein Conjugates: From PEGylation and Beyond Elsevier. pp. 351-385
Dual acting therapeutic proteins for intraocular use
Collins, M., Awwad, S., Ibeanu, N., Khaw, P. T., Guiliano, D., Brocchini, S. and Khalili, H. 2020. Dual acting therapeutic proteins for intraocular use. Drug Discovery Today. 26 (1), pp. 44-55. https://doi.org/10.1016/j.drudis.2020.10.025
Comparative thermodynamic analysis in solution of a next generation antibody mimetic to VEGF
Khalili, H., Brocchini, Steve, Khaw, Peng Tee and Filippov, Sergey K. 2018. Comparative thermodynamic analysis in solution of a next generation antibody mimetic to VEGF. RSC Advances. 8 (62), pp. 35787-35793. https://doi.org/10.1039/C8RA07059H
Storage Stability Studies of Anti-VEGF FpF Antibody Mimetics
Khalili, H., Brocchini, Steve, Khaw, Peng Tee and Filippov, Sergey 2016. Storage Stability Studies of Anti-VEGF FpF Antibody Mimetics. 2016 AAPS Annual Meeting and Exposition. Denver, Co, USA 13 - 17 Nov 2016 American Association of Pharmaceutical Scientists.
An anti-TNF--α antibody mimetic to treat ocular inflammation
Khalili, H., Lee, Richard W., Khaw, Peng Tee, Brocchini, Steve, Dick, Andrew D. and Copland, David A. 2016. An anti-TNF--α antibody mimetic to treat ocular inflammation. Scientific Reports. 6 (36905). https://doi.org/10.1038/srep36905
Fc-fusion mimetics
Khalili, H., Khaw, P. T. and Brocchini, S. 2016. Fc-fusion mimetics. Biomaterials Science. 4 (6), pp. 943-947. https://doi.org/10.1039/C6BM00077K
Storage stability of bevacizumab in polycarbonate and polypropylene syringes
Khalili, H., Sharma, Garima, Froome, Andrew, Khaw, Peng Tee and Brocchini, Steve 2015. Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye. 29 (6), pp. 820-827.